Schedule 13G ownership disclosure

EVAXION BIOTECH A/S

American Depositary Shares, each representing fifty Ordinary Shares, DKK 0.25 nominal value per share · CUSIP: 29970R204

Event date: 2025-01-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Merck & Co., Inc.

    Shares: 63,004,142.00 · Class: 19.96%

  • Merck Sharp & Dohme LLC

    Shares: 63,004,142.00 · Class: 19.96%

  • Merck Global Health Innovation Fund, LLC

    Shares: 63,004,142.00 · Class: 19.96%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-008629
Form type
SCHEDULE 13G/A
Filer
Evaxion Biotech A/S
CIK
CIK 1828253
Filed
Feb 03, 2025
Reporting period
Jan 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub